Enzo Phase II Crohn's data

ENZ said its Alequel met the endpoints of clinical response and clinical remission in a Phase II trial in Crohn's disease. In the double-blind trial, data from 26 evaluable patients showed that 67% of those given Alequel had a clinical response compared with 43% of placebo patients. Also, 58% of Alequel patients had clinical remission compared with 29% of placebo patients. ...